EyePoint Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- EyePoint Pharmaceuticals's estimated annual revenue is currently $3M per year.
- EyePoint Pharmaceuticals received $60.0M in venture funding in February 2019.
- EyePoint Pharmaceuticals's estimated revenue per employee is $21,613
- EyePoint Pharmaceuticals's total funding is $392.9M.
Employee Data
- EyePoint Pharmaceuticals has 137 Employees.
- EyePoint Pharmaceuticals grew their employee count by -10% last year.
EyePoint Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Head Information Technology | Reveal Email/Phone |
2 | VP Quality | Reveal Email/Phone |
3 | VP, Market Access Strategy | Reveal Email/Phone |
4 | VP & Counsel: Securities, Corporate Governance & Strategic Transactions | Reveal Email/Phone |
5 | VP, Chief Staff | Reveal Email/Phone |
6 | VP, Clinical Operations | Reveal Email/Phone |
7 | VP, Early Product Commercialization | Reveal Email/Phone |
8 | VP, Intellectual Property | Reveal Email/Phone |
9 | Director, Clinical Science | Reveal Email/Phone |
10 | Director, Field Reimbursement | Reveal Email/Phone |
EyePoint Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products. As a leading provider of miniaturized, sustained-release drug delivery products, we focus on improving the lives of patients with serious eye disorders in indications with high unmet medical need. With 3 FDA-approved sustained release treatments in ophthalmology we continue to push the evolution of our Durasert Technology platform to further enhance treatments for wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
$392.9M
Total Funding
137
Number of Employees
$3M
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
EyePoint Pharmaceuticals News
WATERTOWN, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Apr 18, 2022. Published: Apr 18, 2022. WATERTOWN, Mass., April 18,...
EyePoint Pharmaceuticals to Participate in Fireside Chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference.
WATERTOWN, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the closing of the previously ann ...
Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) was the target of a significant increase in short interest during the month of July. As of July 31st, ...
Other Companies in Watertown
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $52M | 144 | 10% | N/A |
#2 | $28.9M | 146 | 6% | N/A |
#3 | $53.7M | 148 | 7% | N/A |
#4 | $47.9M | 150 | 6% | N/A |
#5 | $75M | 150 | 8% | N/A |
EyePoint Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2011-01-20 | $10.8M | Undisclosed | Rodman & Renshaw LLC | Article |
| 2012-08-03 | $5.4M | Undisclosed | Rodman & Renshaw LLC | Article |
| 2013-07-22 | $10.8M | Undisclosed | Article | |
| 2014-03-14 | $7.0M | Undisclosed | RA Capital | Article |
| 2014-10-28 | $25.0M | Undisclosed | Article | |
| 2019-02-14 | $60.0M | Undisclosed | CR Group L.P. | Article |